Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TP1736 |
Fibrinogen-Binding Peptide
|
||
Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen, a soluble plasma protein, is a cofactor in platelet activation. It is converted | |||
TP1736L |
Fibrinogen-Binding Peptide fb-acetate
Fibrinogen-Binding Peptide (137235-80-4 fb-acetate) |
Others | Others |
Fibrinogen-Binding Peptide 137235-80-4(fb-acetate) 是纤维蛋白原受体上玻连蛋白结合位点的推定肽模拟物。它结合纤维蛋白原并抑制血小板与纤维蛋白原的粘附和血小板聚集,还抑制血小板与玻连蛋白的粘附 | |||
TP1778 |
Fibrinogen Binding Inhibitor Peptide
|
||
Fibrinogen Binding Inhibitor Peptide, a synthetic dodecapeptide, represents the specific platelet receptor recognition site of the human fibrinogen g-chain (residues 400-411). | |||
TP1458L |
Arg-Gly-Glu-Ser acetate(93674-97-6 free base)
|
Others | Others |
Arg-Gly-Glu-Ser acetate(93674-97-6 free base) 是一种 RGD 相关肽,可控制纤维蛋白原与活化血小板结合的 RGDS 活性。 | |||
T26629 |
Angstrom6
A-6,A 6 peptide,A6,A 6,A6 peptide,A-6 peptide |
PAI-1 | Metabolism |
Angstrom6 (A-6 peptide) 是一种从单链尿激酶纤溶酶原激活剂(scuPA)中提取的 8 肽,它能干扰 uPA/uPAR 级联反应并抑制下游效应。Angstrom6 具有抗肿瘤活性,能通过与 CD44 结合并调节 CD44 介导的细胞信号传导,抑制肿瘤细胞的迁移、侵袭和转移。 | |||
TP1458 |
Arg-Gly-Glu-Ser
|
||
Arg-Gly-Glu-Ser is a RGD related peptide that is a control for the RGDS activity of fibrinogen binding to activated platelets. | |||
T81985 |
K-Casein (106-116),bovine
|
||
K-Casein (106-116), bovine,为一抗血小板聚集与纤维蛋白原结合的多肽,动脉粥样硬化关键作用因子。 | |||
T78001 |
Arg-Gly-Glu-Ser TFA
|
||
Arg-Gly-Glu-Ser TFA,作为RGD相关多肽,调节RGDS对纤维蛋白原及活化血小板结合的抑制作用。 |